ArticleLeukemia2002
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death.
Article in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 112 citations in OpenAlex.
- Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.Journal of cutaneous pathology · 2012Trial
- Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.Journal of translational medicine · 2026Article
- Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.Blood · 2022Article
- CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome.Blood advances · 2022Article
- The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.International journal of molecular sciences · 2022Review
- CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.Frontiers in immunology · 2022Review
- How galectins have become multifunctional proteins.Histology and histopathology · 2020Review
- Morniga-G, a T/Tn-Specific Lectin, Induces Leukemic Cell Death via Caspase and DR5 Receptor-Dependent Pathways.International journal of molecular sciences · 2019Article
- Galectins: their network and roles in immunity/tumor growth control.Histochemistry and cell biology · 2017Review
- Lectins: getting familiar with translators of the sugar code.Molecules (Basel, Switzerland) · 2015Review
- The effects of galectin-1 on the gene expression of the transcription factors TBX21, GATA-3, FOXP3 and RORC.Molecular and cellular biochemistry · 2015Article
- The emerging role of Twist proteins in hematopoietic cells and hematological malignancies.Blood cancer journal · 2014Review
- Introduction to glycopathology: the concept, the tools and the perspectives.Diagnostic pathology · 2014Review
- Galectins and their ligands: negative regulators of anti-tumor immunity.Glycoconjugate journal · 2012Review
- Adhesion/growth-regulatory galectins in the human eye: localization profiles and tissue reactivities as a standard to detect disease-associated alterations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Article
- Article
- Open Wound Healing In Vivo: Monitoring Binding and Presence of Adhesion/Growth-Regulatory Galectins in Rat Skin during the Course of Complete Re-Epithelialization.Acta histochemica et cytochemica · 2011Article
- Ganglioside GM1 deficiency in effector T cells from NOD mice induces resistance to regulatory T-cell suppression.Diabetes · 2011Article
- Galectins in hematological malignancies.American journal of blood research · 2011Article
- Hydrodynamic properties of human adhesion/growth-regulatory galectins studied by fluorescence correlation spectroscopy.Biophysical journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In early stages of cutaneous T cell lymphoma (Sézary syndrome) both CD4+CD7- and CD4+CD7+ T cells clonally expand whereas in late stages of the disease CD7- cells are predominant in number, giving rise to the question whether CD7- T cells have a survival advantage in the skin. Galectin-1, a cell-bound lectin, was recently reported to trigger apoptosis in activated CD7+ T cells. Here, we demonstrate that in contrast to activated CD7(+) T cells, quiescent and activated CD69+ CD7- T cells from healthy donors and from Sézary patients are resistant to galectin-1-mediated cell death. CD7- T cells are apoptosis-resistant even during coculture with IFN-gamma-stimulated endothelial cells that constitutively express galectin-1 in high amounts. These data imply that resistance of CD7- T cells to galectin-1-induced apoptosis may contribute to the accumulation of CD7- Sézary T cells during progression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.